Document ID: chunk:federal_register_of_legislation:F2021L00621:reg:9:p1
Version: federal_register_of_legislation:F2021L00621
Segment Type: reg
Provision Reference: reg 9 (pt 1/2)
Character Range: 3720–6593

9               Factors that must exist
At least one of the following factors must exist before it can be said that, on the balance of probabilities, IgA nephropathy or death from IgA nephropathy is connected with the circumstances of a person's relevant service:
(1)          having cirrhosis of the liver or chronic liver disease at the time of the clinical onset of IgA nephropathy;
Note: chronic liver disease is defined in the Schedule 1 - Dictionary.
(2)          having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical onset of IgA nephropathy;
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
(3)          having a malignant neoplasm at the time of the clinical onset of IgA nephropathy;
(4)          taking a drug which is associated in the individual with the clinical onset of IgA nephropathy during drug therapy and either:
(a)          the improvement of IgA nephropathy within 3 months of discontinuing or tapering drug therapy; or
(b)          the redevelopment of IgA nephropathy on rechallenge with the same drug; and
where taking the drug continued for at least the 7 days before the clinical onset of IgA nephropathy;
(5)          taking a biologic agent for the treatment of cancer or autoimmune disease for at least the 7 days before the clinical onset of IgA nephropathy;
Note: biologic agent is defined in the Schedule 1 - Dictionary.
(6)          undergoing kidney transplantation before the clinical onset of IgA nephropathy;
(7)          having cirrhosis of the liver or chronic liver disease at the time of the clinical worsening of IgA nephropathy;
Note: chronic liver disease is defined in the Schedule 1 - Dictionary.
(8)          having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical worsening of IgA nephropathy;
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
(9)          having a malignant neoplasm at the time of the clinical worsening of IgA nephropathy;
(10)      taking a drug which is associated in the individual with the clinical worsening of IgA nephropathy during drug therapy and either:
(a)          the improvement of IgA nephropathy within 3 months of discontinuing or tapering drug therapy; or
(b)          the worsening of IgA nephropathy on rechallenge with the same drug; and
where taking the drug continued for at least the 7 days before the clinical worsening of IgA nephropathy;
(11)      taking a biologic agent for the treatment of cancer or autoimmune disease for at least the 7 days before the clinical worsening of IgA nephropathy;
Note: biologic agent is defined in the Schedule 1 - Dictionary.
(12)      undergoing kidney transplantation before the clinical worsening of IgA nephropathy;
(13)      being overweight or obese for at least